Hippo Pathway | sciencenewsnet.in

Breaking News

Penn Study Highlights Inconsistencies of Genetic Markers for Predicting Heart Disease

New study shows how salmonella tricks gut defenses to cause infection

How ecDNA Fuels Cancer by Breaking the Laws of Biology

Creating a spatial map of the sea

Much Ado About Vacuum

Researchers Uncover Achilles Heel of Antibiotic-Resistant Bacteria

HSS Appoints Daphne A. Scott, MD, Chief of Primary Sports Medicine

Study: Coronary Function Testing Improves Diagnosis of Heart Disease in Women

Multi-disciplinary teams respond to recent hurricanes to measure real time impacts of storm surge, waves

New pathways for Alzheimer’s prevention

17 Nov, 2024

AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers

April 16, 2023 sarah JonasResearch Results

The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center.